Search

Your search keyword '"Weiß, Sarah"' showing total 567 results
Start Over Author "Weiß, Sarah"
567 results on '"Weiß, Sarah"'

2. Index

Author

Weiss, Sarah

Published
2019

4. Notes

Author

Weiss, Sarah

Published
2019

8. Afterword

Author

Weiss, Sarah

Published
2019

13. Contents

Author

Weiss, Sarah

Published
2019

16. Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control

Author

Weiss, Sarah A., Huang, Amy Y., Fung, Megan E., Martinez, Daniela, Chen, Alex C. Y., LaSalle, Thomas J., Miller, Brian C., Scharer, Christopher D., Hegde, Mudra, Nguyen, Thao H., Rowe, Jared H., Osborn, Jossef F., Patterson, Dillon G., Sifnugel, Natalia, Mei-An Nolan, C., Davidson, Richard A., Schwartz, Marc A., Bally, Alexander P. R., Neeld, Dennis K., LaFleur, Martin W., Boss, Jeremy M., Doench, John G., Nicholas Haining, W., Sharpe, Arlene H., and Sen, Debattama R.

Published
2024
Full Text
View/download PDF

18. Water in peripheral TM-interfaces of Orai1-channels triggers pore opening

Author

Hopl, Valentina, Tiffner, Adéla, Wutscher, Armin, Sallinger, Matthias, Grabmayr, Herwig, Prantl, Magdalena, Fröhlich, Maximilian, Söllner, Julia, Weiß, Sarah, Najjar, Hadil, Nazarenko, Yuliia, Harant, Selina, Kriško, Natalia, Fahrner, Marc, Humer, Christina, Höglinger, Carmen, Krobath, Heinrich, Bonhenry, Daniel, and Derler, Isabella

Published
2024
Full Text
View/download PDF

23. Analyzing Javanese Grimingan: Seeking Form, Finding Process

Author

Weiss, Sarah

Subjects
Music, M1-5000
Abstract

In some styles of Javanese wayang kulit, grimingan flows forth from the hands of the gender player for nearly four of the eight or so hours that comprise an all-night performance. Although their performances are regularly punctuated by other musical events, sometimes a gender player will be asked to perform grimingan for 30-40 minutes without pause. How does a musician generate such an extended solo performance? It turns out that the answer depends on whom you ask. Some performers say that you can play anything as long as it is in the correct mode or pathet. Other gender players tell you that they just keep repeating ‘the melody.’ Through interviews and recording sessions, it gradually became clear to me that each performer did possess a collection of melodies designated for use in the creation of grimingan segments. Working outward from transcriptions of different performers’ grimingan melodies in what they described as their most compact form, and by transcribing more than 50 hours of performance, I have documented the process by which performers expand their versions of compact melodies to fill the necessary minutes of accompaniment. While their approaches to the process are necessarily idiosyncratic, a few rules can be derived to describe the process in each mode. Transcription and analysis have revealed the process by which the performers created their music. Understanding the process revealed the flexible but identifiable nature of the form of grimingan.

Published
2011

25. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study

Author

Kafka, Mona, Giannini, Giulia, Artamonova, Nastasiia, Neuwirt, Hannes, Ofner, Heidemarie, Kramer, Gero, Bauernhofer, Thomas, Luger, Ferdinand, Höfner, Thomas, Loidl, Wolfgang, Griessner, Hubert, Lusuardi, Lukas, Bergmaier, Antonia, Berger, Andreas, Winder, Thomas, Weiss, Sarah, Bauinger, Severin, Krause, Steffen, Drerup, Martin, Heinrich, Elmar, Schneider, Magdalena, Madersbacher, Stephan, Vallet, Sonia, Stoiber, Franz, Laimer, Sarah, Hruby, Stephan, Schachtner, Gert, Nagele, Udo, Lenart, Sebastian, Ponholzer, Anton, Pfuner, Jacob, Wiesinger, Clemens, Kamhuber, Christoph, Müldür, Ecan, Bektic, Jasmin, Horninger, Wolfgang, and Heidegger, Isabel

Published
2024
Full Text
View/download PDF

26. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Author

Djureinovic, Dijana, Weiss, Sarah A., Krykbaeva, Irina, Qu, Rihao, Vathiotis, Ioannis, Moutafi, Myrto, Zhang, Lin, Perdigoto, Ana L., Wei, Wei, Anderson, Gail, Damsky, William, Hurwitz, Michael, Johnson, Barbara, Schoenfeld, David, Mahajan, Amit, Hsu, Frank, Miller-Jensen, Kathryn, Kluger, Yuval, Sznol, Mario, Kaech, Susan M., Bosenberg, Marcus, Jilaveanu, Lucia B., and Kluger, Harriet M.

Published
2023
Full Text
View/download PDF

28. Monitoring the acoustic ecology of the shelf break of Georges Bank, Northwestern Atlantic Ocean: New approaches to visualizing complex acoustic data

Author

Weiss, Sarah G, Cholewiak, Danielle, Frasier, Kaitlin E, Trickey, Jennifer S, Baumann-Pickering, Simone, Hildebrand, John A, and Van Parijs, Sofie M

Subjects
Environmental Management, Environmental Sciences, Human Society, Policy and Administration, Political Science, Life Below Water, Soundscapes, Acoustic niche, Cetaceans, Anthropogenic noise, Data visualization, Communication masking, Environmental Science and Management, Law, Fisheries, Environmental management, Policy and administration, Political science
Published
2021

29. Vice presidential debate sparks satisfaction from students at on-campus watch parties - The Pitt News

Author

Weiss, Sarah GeorgeKatie HovanNaomi

Subjects
Political parties, Students -- Political aspects -- Political activity, Student loans -- Political aspects, Campaign debates -- Political aspects, Vice-Presidential candidates -- Political aspects -- Political activity, News, opinion and commentary, Sports and fitness
Abstract

Byline: Sarah GeorgeKatie HovanNaomi Weiss Hundreds of students attended watch parties across campus to see Ohio Sen. JD Vance and Minnesota Gov. Tim Walz face off on Tuesday night at [...]

Published
2024

34. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Author

Kugel, Curtis H, Douglass, Stephen M, Webster, Marie R, Kaur, Amanpreet, Liu, Qin, Yin, Xiangfan, Weiss, Sarah A, Darvishian, Farbod, Al-Rohil, Rami N, Ndoye, Abibatou, Behera, Reeti, Alicea, Gretchen M, Ecker, Brett L, Fane, Mitchell, Allegrezza, Michael J, Svoronos, Nikolaos, Kumar, Vinit, Wang, Daniel Y, Somasundaram, Rajasekharan, Hu-Lieskovan, Siwen, Ozgun, Alpaslan, Herlyn, Meenhard, Conejo-Garcia, Jose R, Gabrilovich, Dmitry, Stone, Erica L, Nowicki, Theodore S, Sosman, Jeffrey, Rai, Rajat, Carlino, Matteo S, Long, Georgina V, Marais, Richard, Ribas, Antoni, Eroglu, Zeynep, Davies, Michael A, Schilling, Bastian, Schadendorf, Dirk, Xu, Wei, Amaravadi, Ravi K, Menzies, Alexander M, McQuade, Jennifer L, Johnson, Douglas B, Osman, Iman, and Weeraratna, Ashani T

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Vaccine Related, Immunization, Aging, 2.1 Biological and endogenous factors, Aetiology, Age Factors, Animals, Antineoplastic Agents, Immunological, Biomarkers, Tumor, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Immunomodulation, Melanoma, Mice, Mice, Transgenic, Neoplasms, Programmed Cell Death 1 Receptor, T-Lymphocytes, Regulatory, Tumor Microenvironment, Xenograft Model Antitumor Assays, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Purpose: We have shown that the aged microenvironment increases melanoma metastasis, and decreases response to targeted therapy, and here we queried response to anti-PD1.Experimental Design: We analyzed the relationship between age, response to anti-PD1, and prior therapy in 538 patients. We used mouse models of melanoma, to analyze the intratumoral immune microenvironment in young versus aged mice and confirmed our findings in human melanoma biopsies.Results: Patients over the age of 60 responded more efficiently to anti-PD-1, and likelihood of response to anti-PD-1 increased with age, even when we controlled for prior MAPKi therapy. Placing genetically identical tumors in aged mice (52 weeks) significantly increased their response to anti-PD1 as compared with the same tumors in young mice (8 weeks). These data suggest that this increased response in aged patients occurs even in the absence of a more complex mutational landscape. Next, we found that young mice had a significantly higher population of regulatory T cells (Tregs), skewing the CD8+:Treg ratio. FOXP3 staining of human melanoma biopsies revealed similar increases in Tregs in young patients. Depletion of Tregs using anti-CD25 increased the response to anti-PD1 in young mice.Conclusions: While there are obvious limitations to our study, including our inability to conduct a meta-analysis due to a lack of available data, and our inability to control for mutational burden, there is a remarkable consistency in these data from over 500 patients across 8 different institutes worldwide. These results stress the importance of considering age as a factor for immunotherapy response. Clin Cancer Res; 24(21); 5347-56. ©2018 AACR See related commentary by Pawelec, p. 5193.

Published
2018

35. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Author

Stamatouli, Angeliki M, Quandt, Zoe, Perdigoto, Ana Luisa, Clark, Pamela L, Kluger, Harriet, Weiss, Sarah A, Gettinger, Scott, Sznol, Mario, Young, Arabella, Rushakoff, Robert, Lee, James, Bluestone, Jeffrey A, Anderson, Mark, and Herold, Kevan C

Subjects
Pancreas, Animals, Humans, Neoplasms, Pancreatitis, Ketosis, Diabetes Mellitus, Type 1, Autoimmune Diseases, Genetic Predisposition to Disease, Insulin, Isoantibodies, HLA-DR4 Antigen, Hypoglycemic Agents, Genotype, Models, Immunological, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Immunological, B7-H1 Antigen, Insulin Secretion, Endocrinology & Metabolism, Medical and Health Sciences
Abstract

Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two academic institutions and identified 27 patients in whom this developed, or an incidence of 0.9%. The patients had a variety of solid-organ cancers, but all had received either anti-PD-1 or anti-PD-L1 antibodies. Diabetes presented with ketoacidosis in 59%, and 42% had evidence of pancreatitis in the peridiagnosis period. Forty percent had at least one positive autoantibody and 21% had two or more. There was a predominance of HLA-DR4, which was present in 76% of patients. Other immune adverse events were seen in 70%, and endocrine adverse events in 44%. We conclude that autoimmune, insulin-dependent diabetes occurs in close to 1% of patients treated with anti-PD-1 or -PD-L1 CPIs. This syndrome has similarities and differences compared with classic type 1 diabetes. The dominance of HLA-DR4 suggests an opportunity to identify those at highest risk of these complications and to discover insights into the mechanisms of this adverse event.

Published
2018

43. A Content Analysis to Inform Engineering LibGuide Overhaul

Author

DiCiesare, Leah, DiCiesare, Leah, Weiss, Sarah, DiCiesare, Leah, DiCiesare, Leah, and Weiss, Sarah

Abstract

LibGuides are a commonly used tool for aggregating library resources by topic, but they can vary widely. Before making a concerted effort to update and improve the LibGuides at our institution, we are conducting a content analysis to discover current trends in the composition of engineering LibGuides at other R1 institutions. In this lightning talk, we will detail the beginnings of this project: the reasoning for this study, a review of the literature, decisions about what LibGuides we are choosing to look at, and our proposed methodology.

Published
2024

45. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study

Author

Ecke, Thorsten H., Meisl, Christina J., Schlomm, Thorsten, Prof., Rabien, Anja, Labonté, Flora, Rong, Dezhi, Hofbauer, Sebastian, Friedersdorff, Frank, Prof., Sommerfeldt, Lilli, Gagel, Nella, Gössl, Andreas, Barski, Dimitri, Otto, Thomas, Prof., Grunewald, Camilla M., Niegisch, Günter, Prof., Hennig, Martin J.P., Kramer, Mario W., Prof., Koch, Stefan, Prof., Roggisch, Jenny, Hallmann, Steffen, Weiß, Sarah, Waldner, Michael, Graff, Johannes, Veltrup, Elke, Linden, Friederike, Hake, Roland, Eidt, Sebastian, and Wirtz, Ralph M.

Published
2023
Full Text
View/download PDF

46. Trial Protocol 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

47. Supplementary Data 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

48. Data from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

49. Supplementary Figure 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results